Twitter universal website tag code Twitter website tag code

[Skip to content]

Private hospital continually investing in advanced diagnostic and treatment technologies
Search our Site

Medical Oncologist Thomas Newsom-Davies, Private Clinic Treatment, Self Pay Patients

Dedicated GP referral service

Call Cromwell Direct to make a referral on

+44 (0)800 783 9229

More about Cromwell Direct

Make a referral

Refer a patient to us by telephone, fax or email

How to refer

Make an appointment

8am-8pm Monday to Friday
8am-2pm Saturday
Call our Contact Centre on

+44 (0)20 7460 5700

Contact Us

Dr Thomas Newsom-Davis, Consultant Medical Oncologist

Specialist Details
Full name

Dr Thomas Newsom-Davis




Consultant Medical Oncologist


Oncology - medical

Site specialisation

Lung Cancer

Site specialisation 2
Clinical interests

Thoracic malignancies: lung cancer, mesothelioma, thymic malignancies.

Background Information

Tom Newsom-Davis is a consultant in medical oncology, specialising thoracic cancer. He has an active clinical trials programme, and holds a number of national roles including leading the RM Partners lung cancer group which represents all NHS hospitals in South.

Languages spoken


Regular Cromwell clinics


Clinic days

Mon: Tue: Wed: Thurs: Fri: Sat:

Appointments telephone number

(0)20 7317 2662

Additional Career Information
Year qualified



American Society of Clinical Oncology, Association of Cancer Physicians, British Thoracic Oncology Group, British Medical Association, European Society of Medical Oncology, International Association for the Study of Lung Cancer, National Cancer Research Institute.

NHS hospitals

Chelsea and Westminster


Consultant Medical Oncologist, Chelsea and Westminster Hospital, London

Research interests

Immunotherapy, Targeted therapies for lung cancer.

Key published papers

Lebre MC, Vieira PL, Tang MW, Aarrass S, Helder B, Newsom-Davis T, Tak PP, Screaton GR. Synovial IL-21/TNF-producing CD4 T cells induce joint destruction in rheumatoid arthritis by inducing matrix metalloproteinase production by fibroblast-like synoviocytes. J Leukoc Biol. 2017 Mar;101(3):775-783. Berardi R, Santoni M, Newsom-Davis T, Caramanti M, Rinaldi S, Tiberi M, Morgese F, Torniai M, Pistelli M, Onofri A, Bower M, Cascinu S. Hyponatremia normalization as an independent prognostic factor in patients with advanced non-small cell lung cancer treated with first-line therapy. Oncotarget. 2017 Apr 4;8(14). Mok TS, Wu Y-L, Ahn M-J, Garassino MC, Kim HR, Ramalingam SS, Shepherd FA, He Y, Akamatsu H, Theelen WS, Lee CK, Sebastian M, Templeton A, Mann H, Marotti M, Ghiorghiu S, Papadimitrakopoulou VA; AURA3 Investigators (as AURA3 Investigator). Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. N Engl J Med. 2017 Feb16;376(7):629-640. doi: 10.1056/NEJMoa1612674. Epub 2016 Dec 6. Pinato DJ, Newsom-Davis T. Regression of Paraneoplastic Rash after Lung Cancer Chemotherapy. J Thorac Oncol. 2018;13(1):139-140.  Talbot T, Dangoor A, Shah R, Naik J, Talbot D, Lester JF, Cipelli R, Hodgson M, Patel A, Summerhayes M, Newsom-Davis T. The burden of neutropenic sepsis in patients with advanced non-small cell lung cancer treated with single-agent docetaxel: A retrospective study. Lung Cancer 2017; 113:115-120.


Media coverage

Our health professionals regularly contribute to hospital publications, as well as national newspaper articles and television coverage.